Project Grant R44EY037603
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$913K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
This federal Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $713,964 to The Regents of the University of California, San Francisco (UCSF) to develop a prototype for an accurate, safe, and wearable 24-hour intraocular pressure (IOP) monitoring device. The key objectives are to: 1) develop a contact lens-based IOP sensor using atomic force microscopy; 2) create an empirical model relating sensor indentation measurements to IOP; and 3) assess the...
This $332,179 Project Grant awarded by the National Eye Institute (CFDA 93.867 Vision Research) supports the development of nanobarrier contact lenses that can provide sustained delivery of the drug cysteamine to treat the ocular complications of cystinosis. The lenses are designed to replace the current 8-times daily eye drop regimen, improving patient compliance and reducing side effects from the preservatives and acidic pH in the eye drops. The project aims to demonstrate the lenses can...
This federal Project Grant award of $306,118 from the National Eye Institute (CFDA 93.867 - Vision Research) aims to develop a drug screening platform using functional human donor eyes to improve the translation probability of investigational new drugs (INDs) for blinding diseases. The project has two key objectives: Establish novel ex vivo preclinical models for human ocular diseases by restoring and preserving in vivo-like light responsiveness in postmortem human eyes for over 48 hours....
This Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $1,066,178 to Tavo Biotherapeutics, Inc. (operating as Oculo Therapy LLC) to support late-stage preclinical development and GMP production of a novel extended-release intraocular pressure (IOP)-lowering formulation for the treatment of glaucoma. The funding will enable critical IND-enabling studies for this first-in-class drug candidate using the FDA-approved drug pregabalin as...
The National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), awarded a $300,001 Project Grant to Kineolabs, Inc. in Billerica, MA. The objective of this 1-year grant, which runs from July 1, 2025 to June 30, 2026, is to develop a portable, low-cost line-scan swept-source optical coherence tomography (LS-SS-OCT) imaging system. This system is intended for early detection and monitoring of age-related macular degeneration (AMD), diabetic retinopathy, and other eye...
This federal Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $881,796 to Siloam Vision, Inc. to develop two advanced, laser-based, AI-enabled retinal imaging systems. The key innovations are: A wider field-of-view camera design that can be paired with either a scanning laser ophthalmoscope (SLO) or optical coherence tomography (OCT) system, offering 2D or 3D imaging, respectively. This aims to address an unmet need in retinopathy...
This federal Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) aims to develop an "Attentive Knowledge Device for Visual Assistance" that leverages artificial intelligence (AI) and computer vision technologies to better assist persons with visual impairment. The $602,198 award, effective July 1, 2025 through June 30, 2027, will fund the University of Southern California to: 1) engage partners to select optimal machine vision algorithms for real-time...
Aisight Health Inc. received a $479,580 Project Grant award from the National Institutes of Health's National Eye Institute to develop artificial intelligence tools to identify rapid glaucoma progression. The goal is to use machine learning models trained on over a decade of optical coherence tomography images, visual field tests, and clinical records for more than 9,000 glaucoma patients to more accurately and quickly determine which patients are likely to experience rapid vision loss from...
This $185,000 Project Grant award from the National Eye Institute (NEI) under CFDA 93.867 (Vision Research) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The primary awardee, the University of North Texas Health Science Center at Fort Worth, will employ computational pharmacology approaches to identify small molecule inhibitors that can interfere with the GREM1-BMP protein-protein interaction, a key pathogenic mechanism contributing...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), aims to develop a refillable micromachined lens capsule-based drug delivery device for extended intraocular delivery of biologics and immune-modulating peptides to treat non-infectious uveitis. The $257,785 award to The Leland Stanford Junior University (Stanford University) will support research to characterize and control the release of adalimumab and a novel...